




The relative strengths and weaknesses of Sarepta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 6.2% points. The greatest weakness of Sarepta Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 146%, being 99% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	2,557,861
Cost of Goods Sold	0
Intangible Assets	7,578
Liabilities, Current	619,604
Liabilities, Non-Current	542,620
Other Assets	382,890
Other Compr. Net Income	-1,644
Other Expenses	154,228
Other Liabilities	1,581,192
Other Net Income	-153,762
Other Revenues	933,013
Property and Equipment	180,037
Research and Development	877,090
Selling, General and Administrative Expense	451,421

Output Variable	Value in 1000 USD
Assets	3,128,366
Liabilities	2,743,416
Expenses	1,482,739
Revenues	933,013
Stockholders Equity	384,950
Net Income	-703,488
Comprehensive Net Income	-704,310
BaseVar	4,221,470
ECR before LimitedLiability	4.6%
Economic Capital Ratio	146%